share_log

B. Riley Securities Downgrades Infinity Pharmaceuticals to Neutral, Lowers Price Target to $1.5

B. Riley Securities Downgrades Infinity Pharmaceuticals to Neutral, Lowers Price Target to $1.5

B.萊利證券將無限制藥評級下調至中性,將目標價下調至1.5美元
Benzinga Real-time News ·  2022/11/16 13:04

B. Riley Securities analyst Kalpit Patel downgrades Infinity Pharmaceuticals (NASDAQ:INFI) from Buy to Neutral and lowers the price target from $3 to $1.5.

B.萊利證券分析師卡爾皮特·帕特爾將無限制藥(納斯達克:INFI)的評級從買入下調至中性,並將目標價從3美元下調至1.5美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論